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Abstract
Background: The challenge of finding practical, patient-rated outcome measures is a key issue in
the evaluation of health care systems and interventions. The ORIDL (Outcome in Relation to
Impact on Daily Living) instrument (formerly referred to as the Glasgow Homoeopathic Hospital
Outcomes Scale or GHHOS) has been developed to measure patient's views of the outcome of
their care by asking about change, and relating this to impact on daily life. The aim of the present
paper is to describe the background and potential uses of the ORIDL, and to report on its
preliminary validation in a series of three studies in secondary and primary care.
Methods: In the first study, 105 patients attending the Glasgow Homoeopathic Hospital (GHH)
were followed-up at 12 months and changes in health status were measured by the EuroQol
(EQOL) and the ORIDL. In the second study, 187 new patients at the GHH were followed-up at
3, 12, and 33 months, using the ORIDL, the Short Form 12 (SF-12), and the Measure Yourself
Medical Outcome Profile (MYMOP). In study three, 323 patients in primary care were followed for
1 month post-consultation using the ORIDL and MYMOP. In all 3 studies the Patient Enablement
Instrument (PEI) was also used as an outcome measure.
Results: Study 1 showed substantial improvements in main complaint and well-being over 12
months using the ORIDL, with two-thirds of patients reporting improvements in daily living. These
improvements were not significantly correlated with changes in serial measures of the EQOL
between baseline and 12 months, but were correlated with the EQOL transitions measure. Study
2 showed step-wise improvements in ORIDL scores between 3 and 33 months, which were only
weakly associated with similar changes in SF-12 scores. However, MYMOP change scores
correlated well with ORIDL scores at all time points. Study 3 showed similar high correlations
between ORIDL scores and MYMOP scores. In all 3 studies, ORIDL scores were also significantly
correlated with PEI-outcome scores.
Conclusion: There is significant agreement between patient outcomes assessed by the ORIDL and
the EQOL transition scale, the MYMOP, and the PEI-outcome instrument, suggesting that the
ORIDL may be a valid and sensitive tool for measuring change in relation to impact on life.
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Background
The challenge of finding practical, patient-focussed, clini-
cally-relevant outcome measures is a key issue in the
increasing call for patient-centred care and clinical govern-
ance in health systems around the world [1,2]. However,
there are relatively few patient-rated outcome measures
that seek to measure change from the patients' perspec-
tive, using simple concepts such as change in main prob-
lems or symptoms and well-being [3,4]. Furthermore, it is
difficult to know from these measures how meaningful
any reported changes are in terms of impact on the indi-
viduals' daily life.
The ORIDL (Outcome in Relation to Impact on Daily Liv-
ing) instrument measures patients' views of the outcome
of care [5]. Created initially for evaluating experimental
clinics [6], its increasing adoption under its former name,
the Glasgow Homoepathic Hospital Outcome Scale
(GHHOS), in a number of centres [7-11] and studies [12-
17] has created a need to study its validity which has not
previously been explored. It differs from many other
scales by asking about change directly, and by relating
outcome to the effect of the intervention on impact on
daily life. In the present paper we report on a series of
studies in which we have had the opportunity to compare
the ORIDL with three validated measures in secondary
(integrative care) and primary (conventional care) set-
tings.
Methods
The rationale behind the development of the ORIDL was
to base the instrument on the type of dialogue that the
doctor (or other health care professional) and patient
would have to evaluate outcome in the clinical encounter.
For example, a dialogue may be as follows:
Doctor: Well, was there any effect from what we did?
Patient: Yes, I think it helped...
Doctor: Yes, but was it a useful effect? Can you give me an
example?
Patient: Yes, it was really useful, I was able to get about
more and go to the shops.
Doctor: Really? And is that a major change, a really
marked benefit, or is it less than that?
Patient: No, this is really marked, it's the best thing I've
had for the problem. I'm not saying It has cured it or any-
thing, I mean I still have the problem, but I could live with
it now.
The aim was to embed the essence of these dialogues in
the design of the instrument, but allow it to be standard-
ised in a way that would allow a questionnaire based ver-
sion of the scale to measure the participants' opinions on
the effects of the intervention (not their view on the natu-
ral progression of the health problems being considered).
The validation studies took place in the outpatient unit of
GHH, an NHS-funded Centre for Integrative care, and in
primary conventional care in an area of high deprivation
in Glasgow. Ethical approval was obtained for all 3 studies
from the West of Glasgow University NHS Trust. Written
consent was obtained from all patients. In the GHH study
1, four senior doctors took part and the participants were
adult out-patients attending the GHH for various periods
of time (see ref 12 for details). In GHH Study 2, nine doc-
tors took part (not including 2 of the 4 senior doctors who
took part in study 1) and the participants were all new
outpatients above 12 years of age whom the doctors saw
in the 3 months from September to December 2002, as
reported previously [14]. In study 3, five GP Principals
took part working in the same Practice, and the partici-
pants were adult patients registered with the practice.
The ORIDL offers nine options for the participant to
choose. In study 1, the format used to elicit patients' views
was as shown in Figure 1.
In study 2, a different format was used to elicit patients'
views on these 9 options, as shown in Figure 2. This ques-
tion was then repeated for 'your overall well-being'.
In study 3, the format used in study 1 was adopted (Figure
1), but modified to 'the overall effect of your treatment by
your GP' as it was a primary care study of general practi-
tioners.
A score of 2 or above was used as a 'ORIDL threshold'
score as the wording at this level records an effect on qual-
ity of daily living as perceived by the patient.
Choosing timings and targets
The target and timing of use of the ORIDL is chosen by the
participants and the context, and so reporting needs to
make clear what choices were used. We have used ORIDL
in the current studies for patients' views. It is less explored
for recording practitioners own views.
Presenting results
Individual results can be recorded in the medical casenotes
as need be, perhaps beside the intervention they refer to,
or as overall results. This has been useful in clinical prac-
tice at the GHH as a 'shorthand' code allowing the care
team to share a sense of the value or otherwise of interven-
tions. Group results can be presented graphically to showBMC Health Services Research 2007, 7:139 http://www.biomedcentral.com/1472-6963/7/139
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the range of results for a group or cohort of patients, as
reported in the present paper.
Procedure
Immediately before their consultation, the patients were
asked to complete the EQOL [18] (Study 1, GHH) or the
SF-12 [18] (Study 2; GHH) and during the consultation
(with the practitioner) they did the initial MYMOP [3]
(Study 2; GHH, Study 3; Primary Care). After the consul-
tation they completed demographic questions and put the
forms in a sealed collection box. In Study 1, the patients
were posted a follow up questionnaire containing the
EuroQOL and ORIDL (main complaint and well-being) at
12 months after baseline assessment. In Study 2, the
patients were posted follow up questionnaires at 3
months, 12 months and 33 months after initial consulta-
tion (baseline assessment) containing the SF-12,
MYMOP, and ORIDL. In Study 3, patients were posted a
follow up questionnaire at 3–4 weeks after contact consul-
tation (baseline assessment). In studies 1 and 2, non-
responders received two postal reminders, in study 3, 1
postal reminder followed by a telephone call.
Validated measures used to compare with ORIDL
The Measure Yourself Medical Outcome Profile
(MYMOP) has four items which are completed during the
consultation [3]. The patients choose (with regard to their
main problem) up to two main symptoms and one activ-
ity of daily living, which are scored for severity over the
past week on a seven-point scale (from 0 = "As good as it
could be", to 6 = "As bad as it could be"). In a similar way
a general well being question is completed. By adding up
the scores to all the items and dividing the total by the
number of answered items an overall profile score is cal-
culated. On the follow up questionnaire the wording of
the chosen symptoms and activity are copied and scored
again by the patients [3].
The EuroQOL-5D (EQOL) and the Short Form 12 (SF-12)
are both widely used self-completed instruments to meas-
ure health status [18,19]. In the EQOL, five domains
make up the descriptive system of the instrument; mobil-
ity, self-care, usual activities, pain/discomfort, and anxi-
ety/depression. There are three possible responses for each
domain. Results can be presented descriptively, or scores
added to give an un-weighted total score or an index
(weighted) score can be calculated from published tables
to give a co-efficient between zero and one. In addition
the EQOL has a VAS component which asks the patient to
rate their current health status on a visual analogue scale
from 0 (worst imaginable health state) to 100 (best imag-
inable health status). Finally, the EQOL also includes a
transition measure, asking patients to rate their current
health state against the previous 12 months (Better, Same
Worse). In the SF-12, twelve questions comprise several
concepts, such as physical functioning, social functioning,
and bodily pain. The responses are weighted and com-
bined to derive two summary scales: (1) the physical com-
ponent score (PCS), which is an indicator of physical
health (2) the mental component score (MCS), which is
an indicator of mental health. The two scores range
ORIDL format in study 1 Figure 1
ORIDL format in study 1.
The following questions ask you, compared to how you were when you first attended 
GHH, what has been the overall effect of your treatment at Glasgow Homoeopathic 
Hospital on your main complaint, and general feeling of well-being with the problem up 
to the present time?” 
   +4     Cured /Back to normal 
      +3     Major Improvement 
      +2     Moderate improvement, affecting daily living 
      +1     Slight improvement, no effect on daily living 
         0     No change/Unsure 
       -1     Slight deterioration, no effect on daily living 
        -2     Moderate deterioration, affecting daily living 
       -3     Major deterioration 
       -4     Disastrous deterioration 
Please complete the 2 boxes using the scale shown above: 
1.The main complaint for which you came for treatment 
2. Your overall well-beingBMC Health Services Research 2007, 7:139 http://www.biomedcentral.com/1472-6963/7/139
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between 0 and 100 and higher scores imply better overall
health.
The Patient Enablement Instrument (PEI) is a six-item
measure that was developed and validated to measure the
immediate outcome of consultations in primary care [20].
However, we have recently used the PEI to measure
patients views on enablement over time [14] and qualita-
tive work suggests it may be a useful outcome for patients
in terms of changes in self-concept [21]. Therefore we
have reported on the PEI as a longer-term outcome meas-
ure (PEI-Outcome) in the present paper.
Participants
Study 1 (GHH) – patients completed the follow-up study
at 12 months, patient details have been reported else-
where [12,22].
Study 2 (GHH) – patients completed the follow up ques-
tionnaire at three months, at twelve months, and 33
months. Details of the patients characteristics have been
previously reported [14]. An additional time points at 20
months was included using the ORIDL only.
Study 3 (Primary Care) – patients completed the follow
up questionnaire at 1 month.
Analysis
The data were analysed through the statistical package
SPSS. Comparisons between the ORIDL scores with the
change scores (i.e. the difference between the scores from
the first and follow up questionnaires) of the EQOL,
MYMOP and SF-12 was assessed by using Spearman's
rank correlation coefficient. Through independent sam-
ples t-tests it was checked whether people who had scores
below the ORIDL threshold (< +2) had significantly lower
change scores on the MYMOP and SF-12 than the people
who had scores above the ORIDL threshold (+2 and
above).
Results
Study 1: ORIDL and EQOL scores over 12 month
105 patients consented to follow-up, and 74 returned the
questionnaire at 12 months (75% response rate). Of these
74, there were 5 missing values (6.8%) for ORIDL (both
main complaint and well-being). Missing values for
EQOL ranged from 6.8–10.9%, (mean 9.0%).
ORIDL format in study 2 Figure 2
ORIDL format in study 2.
The following questions ask you what the overall effect your treatment has had on your main complaints, 
general feeling of well-being, and your coping with the problem up to present time. The questions are asked 
in such a way that they reflect the dialogue you may have during the consultation with your doctor or 
practitioner. Please, answer the questions by ticking the boxes and then follow either the arrows to the next 
question or the instructions next to boxes. 
1. Your main complaint(s)… (please tick boxes)
No, no change 
(Please go to Q.2) 
Yes, it improved Yes, it got worse
0 -1 +1
2…..……….. “Is/was this change enough to affect the quality of your daily living?”
No, no change 
(Please go to Q.2) 
Yes, it improved Yes, it got worse
-2 +2
3…………………………. “Is/was this change very marked, a major effect?”
4. “Is/was this change a complete resolution or disastrous deterioration of the problem?”
Yes, a major 
improvement 
No, no change 
(Please go to Q.2) 
Yes, a major 
deterioration 
-3 +3
-4 +4
Yes, a complete 
resolution
No, neither  Yes, a disastrous 
deterioration
1. “Has the treatment caused any improvement or deterioration in your main complaint(s)?”BMC Health Services Research 2007, 7:139 http://www.biomedcentral.com/1472-6963/7/139
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Figure 3 shows the distribution of ORIDL scores at 12
months post contact consultation in patients attending
the GHH. The majority of patients reported overall
improvements in their main complaint and well-being,
with some 68% and 77% reporting improvements in
quality of daily living (ORIDL scores of 2+ or better) in
main complaint and well-being, respectively. However,
the lack of a 'ceiling effect' should also be noted, with no
patient recording a score of plus 4 ('cured').
With the EQOL, small but statistically significant
improvements (p < 0.001, chi-squred) between baseline
and follow-up scores were observed for usual activities
(13% of patients showing improvement), pain/discom-
fort (22% showing improvement) and anxiety/depression
(13% showing improvement). No significant changes
were found in mobility or self-care (results not shown). A
significant but small difference in EQOL VAS score was
found between baseline and follow-up (baseline; mean
Health State Today 62.5, follow-up: mean Health State
Today 68.6, p = 0.001) signifying a small improvement in
perceived overall health status. The EQOL transition score
(Health state today compared with 12 months ago)
showed much larger perceived changes, with 66% of
patients reporting 'better', 21 % 'same' and 13% 'worse'
health state.
Table 1 shows the correlations between ORIDL and EQOL
scores. No significant correlations were found between
the ORIDL and the EQOL total score for the change in the
5 domains between baseline and follow-up (calculated as
either a weighted or un-weighted total scores). Changes in
the individual domains of the EQOL were also not signif-
icantly correlated with the ORIDL, except for a weak cor-
relation (rho 0.25, p = 0.04) between EQOL-Mobility and
ORIDL-Well-Being (results not shown). EQOL-VAS
change showed a weak but significant correlation with
ORIDL-wellbeing score but not with ORIDL-main com-
plaint (Table 1). However, EQOL-transitions score (per-
ceived change over the last 12 months) were highly
correlated with both components of the ORIDL (Table 1).
Similarly PEI-Outcome scores (change in enablement
over 12 months) were also significantly related to ORIDL
scores (Table 1). The correlation between ORIDL-main
complaint and ORIDL-well being was 0.724, p < 0.001.
Study 2: ORIDL and MYMOP and SF-12 scores at 3 
months, 12 months, and 33 months in new patients
187 new patients consented to follow-up, and question-
naire response rates were 117 (63%), 76 (41%) and 75
(40%) at 3, 12, and 33 months respectively. Missing val-
ues for ORIDL items at the different time points ranged
from 0.9 – 6.4% (mean 3.4%). Missing values for
MYMOP symptom 1 and well-being items ranged from
Table 1: Spearman's correlations between ORIDL and EQOL at GHH (study 1)
ORIDL-main complaint ORIDL-well being
Change in EQOL Score (un-weighted) 0.201 (63) 0.083 (63)
Change in EQOL Score (Weighted) 0.115 (63) 0.029 (63)
Change in EQOL – VAS 0.152 (64) 0.261 (64) *
EQOL – transition scale 0.643 *** (66) 0.546 (67)***
PEI Outcome 0.418 ***(67) 0.487 (67)***
* p < 0.05, ** p < 0.01, *** p < 0.001
ORIDL scores over 12 months in patients attending the Glas- gow Homoeopathic Hospital (Study 1) Figure 3
ORIDL scores over 12 months in patients attending the Glas-
gow Homoeopathic Hospital (Study 1).
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5.3–15.8% (mean 11.0%) and for SF-12 items from 4.0–
22.4% (mean 13.6%).
Figure 4 shows the ORIDL scores (expressed as % scoring
2+ or above) of new patients attending the GHH followed
prospectively up to 33 months. As can be seen there was a
slow but steady improvement in main complaint and
well-being in terms of effect on daily life over the 33
month period.
The baseline and follow-up scores at 3 months and 12
months for the SF-12 and the MYMOP have been pub-
lished previously (Bikker et al 2005) and showed no
changes in SF-12 scores but significant improvement in
MYMOP scores. Similarly, SF-12 scores showed no signif-
icant changes between baseline and 33 months for either
the physical or mental health components (results not
shown). MYMOP scores did however show significant
improvements (paired t-test) in scores for symptoms
(baseline 4.24, 33 months 3.16, p < 0.001), well-being
(baseline 3.50, 33 months 2.84, p < 0.01), and profile
score (baseline 4.02, 33 months 3.18, p < 0.001).
Table 2 shows the correlations between ORIDL and
MYMOP, SF-12 and PEI-outcome at 3,12, and 33 months.
As can be seen, ORIDL scores were only weakly related to
SF-12 change scores at all 3 time points, with few signifi-
cant correlations. However, ORIDL and MYMOP change
scores were much more highly correlated, showing signif-
icant relationships to each other at all time points and for
all components reported (MYMOP symptom change,
MYMOP well-being change, and MYMOP profile change
all significantly related to both ORIDL main complaint
and ORIDL well-being). There was no indication that the
strength of the correlation between ORIDL and MYMOP
weakened with time (i.e., correlations at 33 months were
as strong, if not stronger, than at 3 months). The strongest
correlations with ORIDL was generally with the change in
MYMOP profile score.
Table 2 also shows that the PEI-outcome measure also
correlated significantly with the ORIDL at 3 months and
12 months (PEI-outcome was not measured at 33
months).
Table 2: Spearman's correlation between ORIDL and SF-12, MYMOP, and PEI at GHH (study 2)
ORIDL – main complaint ORIDL – well being
3 months 12 months 33 months 3 months 12 months 33 months
SF-12 PCS Change 0.214* (90) 0.186 (56) 0.224 (63) 0.211* (90) 0.152 (57) 0.336** (63)
SF-12 MCS 
Change
0.245* (90) 0.015 (56) 0.334** (63) 0.235* (90) 0.040 (57) 0.388** (63)
MYMOP Change 
inProfile
0.444*** (90) 0.474*** (61) 0.499** *(68) 0.400** (99) 0.487** *(62) 0.541*** (68)
MYMOP Change 
in Symptoms
0.433*** (109) 0.444** *(68) 0.440 ** *(70) 0.435** *(109) 0.485*** (69) 0.446***(70)
MYMOP Change 
in Well-Being
0.334** (102) 0.314* (62) 0.390** (64) 0.333** (101) 0.439** *(63) 0.383** (64)
PEI Overall 
Outcome
0.451** (105) 0.586***(62) - 0.528*** (104) 0.640*** (63) -
* p < 0.05, ** p < 0.01, *** p < 0.001
Improvements in daily living reported by the ORIDL over 33  months at GHH (Study 2) Figure 4
Improvements in daily living reported by the ORIDL over 33 
months at GHH (Study 2).
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Study 3 (Primary Care): ORIDL and MYMOP at 1 month 
post-baseline
323 patients consented to follow-up, and 159 returned
the questionnaire at 1 month (49% response rate). Of
these 159, missing values (6.8%) for ORIDL main com-
plaint and well-being items were 10% and 11%, respec-
tively. Missing values for MYMOP symptom 1 and well-
being items ranged from 2.0–7.0% (mean 4.7%). Missing
values for PEI ranged from 2.6–5.0% (mean 4.0).
Figure 5 shows the distribution of ORIDL scores 1 month
after contact consultation in primary care. The percent
reporting a significant impact of daily living for main
complaint is 43% and for well-being is 34%. The percent-
age reporting no change (a score of zero) was 29% for
main complaint and 40% for well-being. This was similar
to the percentage showing no change (a change score of
zero) for the MYMOP (32% for symptom 1, 41% for well-
being).
For MYMOP scores at baseline and 1 month significant
improvements were found in symptom (baseline 4.50, 1
month 3.58, p < 0.001) and profile score (baseline 4.07,1
month 3.64, p < 0.001) but not in well-being (baseline
3.53, 1 month 3.53).
Table 3 shows the relationship between ORIDL and
MYMOP and PEI in primary care. ORIDL components
were highly and significantly correlated with all MYMOP
change scores, with the highest correlations found
between ORIDL -main complaint and MYMOP symptom
change and profile change. A significant relationship
between MYMOP well-being change and the ORIDL items
was also found. PEI-outcome was highly correlated with
the ORIDL items.
The ORIDL threshold score (+2)
Scores of ≥ +2 on the ORIDL denotes a meaningful change
in the outcome to the patient (i.e. sufficient to improve
daily living), so it was hypothesised that patients with
scores of +2 and above would have significantly higher
results on the change scores of the MYMOP compare with
patients with ORIDL scores below +2. As Table 4 shows,
this was the case in all instances in all three studies and at
all time points measured.
Discussion
The development of the ORIDL instrument arose from
directly asking patients questions of clinical relevance:
'Did the treatment work?', 'Was it any good?', 'Is this serv-
ice helping reduce suffering?' Determining outcome is
always challenging, 'proof' changes as it emerges from a
complex of scientific, cultural and personal factors – an
'Evidence Mosaic' – determined as much by who is asking
the question, why and when, as by any abstract notion of
pure science [23]. The ORIDL scale contributes by being
rooted in the patient's experience of how the outcome of
care has affected their daily life. As the scale (under its
former name of GHHOS) has come into use in clinical
and research contexts in recent years by virtue of its high
face validity and practical ease of use, this paper's aim was
to formalise its introduction, comment on its practical
use, and take forward issues of validity.
Table 3: Spearman's correlation of ORIDL with MYMOP and PEI 
in primary care (study 3)
ORIDL-
main 
complaint
ORIDL-
well being
MYMOP Profile Score 0.510*** 0.437***
MYMOP Symptom 1 Score 0.553*** 0.409***
MYMOP Well-Being Score 0.358*** 0.385***
PEI Outcome 0.572*** 0.584***
*** p < 0.001
ORIDL outcomes in primary care at 1 month Figure 5
ORIDL outcomes in primary care at 1 month.
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In the present series of studies, the ORIDL instrument
showed significant and moderate-high correlations with
the MYMOP at all time-points examined and in both the
secondary (integrative) care setting of the GHH (Study 2)
and in the primary (conventional) care setting (Study 3).
This is an important finding, given that the MYMOP is
now a well established instrument used to chart changes
in patients symptoms and well-being, and is known to be
to be more responsive to change than other widely-used
tools such as the SF-36 [3] and the EuroQOL [23]. Fur-
thermore, the consistency of the relationship between the
ORIDL and the MYMOP, even up to 33 months after ini-
tial baseline measurement, suggest a stability to the
changes captured by the ORIDL. This is again of consider-
able importance, given that academic opinion is divided
on the use of transition measures versus serial measures
when measuring health outcome. Whereas some argue
that measuring change retrospectively (as in ORIDL) is
highly fallible because it depends on accurate memory of
the past [24,25], others take the opposite view, with evi-
dence to show that patients' retrospective assessments are
more sensitive, and correlate better with patient satisfac-
tion and physical and biological indicators of change in
disease state [26,27]. These two opposing academic views
of psychometrics and 'clinimetrics' have not been recon-
ciled as yet, and it has been argued that both may be valid
and important depending on the context [20,26]. The
ORIDL scale was created by a clinician (DR) and thus
reflects this direct approach of asking patients about
change, as carried out by clinicians in practice. However,
by anchoring the scale in the concept of improvement in
daily living, it may be that the ORIDL has a meaning not
found in other transition scales.
There was, as we expected, less correlation between the
ORIDL and the EQOL, and the SF12, similar to the weak
relationship shown between the EQOL and the MYMOP
[28] and the SF-36 and the MYMOP [2], reflecting the pre-
viously reported poor sensitivity to change by these two
widely used tools. The significant correlations found
between the EQOL transition scale and the ORIDL, and
the PEI-outcome instrument and the ORIDL are new find-
ings, not reported previously in the literature, though the
use of the PEI as an outcome measure has been reported
previously [14,21].
The response rate in the present series of studies varied,
with a high response rate in study one (75%), but a
diminishing response rate in study two (from 60–40%)
and a 49% response rate in study three. However, we have
no evidence to suggest the lower response rates were
related to the ORIDL. It may well relate to the length of
questionnaire and the context of the study. For example,
study 3 was set in a primary care centre in an area of high
socio-economic deprivation, where low response rates to
postal follow-up is common (S Mercer, unpublished
data). The fact that the number of missing items for
ORIDL was low in all three studies, and around the same
or less than the other instruments (MYMOP, EQOL, SF-
12), would support the face validity of the tool. However,
qualitative work with patients is required to confirm this.
Qualitative work is also required to allow us to establish
the best way of presenting the ORIDL choices to patients.
In the present work study 2 used a different format from
the other two studies (as shown in the methods) but we
have no information at present as to which format
patients find easiest to understand.
Table 4: Mean change in MYMOP profile scores in ORIDL categories 2+ or better versus less than 2+
ORIDL-main complaint P-value ORIDL-well being p-value
MYMOP Change 
(Profile)
< 2+ 2+ or better < 2+ 2+ or better
GHH (3 mths)
Mean
(SD)
n
0.00
(1.38)
73
1.49
(1.17)
26
<0.001 0.14
(1.48)
73
1.09
(1.24)
26
<0.01
GHH 12 mths
Mean
(SD, n)
0.027
(1.47)
47
1.61
(0.98)
14
<0.01 0.38
(1.51)
53
1.58
(0.536)
9
<0.05
GHH 33 mths
Mean
(SD, n)
0.15
(1.49)
32
1.40
(1.27)
36
<0.001 0.32
(1.46)
40
1.48
(1.29)
28
<0.01
GP 1 mth
Mean
(SD, n)
0.25
(1.26)
106
1.31
(1.42)
37
<0.001 0.31
(1.36)
114
0.99
(1.32)
28
<0.001BMC Health Services Research 2007, 7:139 http://www.biomedcentral.com/1472-6963/7/139
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The current data should only be seen as part of a wider pic-
ture of validation. Previous studies have found clinically
coherent correlations between indicators of consultation
quality and outcomes measured by ORIDL [10-12,20]. In
terms of its clinical potential, any measurement scale can
only give a simplified version of what goes on and cannot
hope to capture and represent the richness and complexity
of daily clinical care. However, as a contribution to
patient-centred outcome measures, ORIDL has two key
characteristics. Firstly, it is modelled on how patients and
doctors already assess care in daily practice (i.e., by asking
about change directly), and secondly, it anchors the out-
come to the patient's assessment of significant deteriora-
tion or improvement in terms of daily living.
Further work is required to establish how many patients
are needed per doctor in order to establish a reliable
ORIDL score for individual doctors [25], if a comparison
between doctors is desired. Further qualitative research is
also required to assess patients' views on the ORIDL and
this will be of major importance in trying to validate the
instrument further.
Strengths and weaknesses of the ORIDL
Overall, we feel the scale has the following strengths:
1. It is quick and simple to use and its results are easy to
communicate.
2. It is generic and so flexibly adaptive to different contexts
and targets.
3. It aims to link outcome to the experience of daily living.
4. It models how patients and practitioners already asses
care in daily busy practice.
5. It can be used in routine clinical practice without dis-
rupting the care process.
6. It may allow comparison across different contexts of
healthcare in the degree of useful impact achieved by the
intervention.
7. It establishes a useful shared language, for example,
whatever the context if you say a patient experienced '+2'
then others know that this was change was at least suffi-
cient to impact on the quality of daily living.
8. It can be used without measuring a previous baseline,
capturing the participants' views of any change over time.
Some of its weaknesses are:
1. It is a broad-brush measure (and so lacks detail and pre-
cision) and would often need supplemented by other
measures if more detailed results are needed.
2. It is subjective, even though anchored in experience of
daily living.
3. It is only as good as the participants' views, and shares
all the strengths and weaknesses of ordinary clinical prac-
tice.
4. It focuses only on the participants' views of the impact
of the care – other issues like 'How?', or 'Duration?, or
'Why – e.g: placebo?', or, objective verification – need to
be addressed through other approaches.
5. It can be used without a measured baseline, so is subject
to the bias of recall, and the shift in perception as health
status changes.
Conclusion
Given the current search for appropriate outcome meas-
ures of routine care [29,30] we think it is worthwhile to try
to relate measures of outcome to the patients' view of its
impact on their daily lives. Clearly further work is
required to validate the accuracy of the ORIDL in assess-
ing such change. However, our experience and data to
date suggest that the ORIDL scale may prove of value in
tracking routine care in clinical practice and in evaluating
healthcare interventions.
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